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TLR4 activation initiates a signaling cascade leading to the production of type I IFNs
and of the downstream IFN-stimulated genes (ISGs). Recently, a number of IFN-induced
long non-coding RNAs (lncRNAs) that feed-back regulate the IFN response have been
identified. Dysregulation of this process, collectively known as the “Interferon (IFN)
Response,” represents a common molecular basis in the development of autoimmune
and autoinflammatory disorders. Concurrently, alteration of lncRNA profile has been
described in several type I IFN-driven autoimmune diseases. In particular, both TLR
activation and the upregulation of ISGs in peripheral blood mononuclear cells have
been identified as possible contributors to the pathogenesis of systemic sclerosis
(SSc), a connective tissue disease characterized by vascular abnormalities, immune
activation, and fibrosis. However, hitherto, a potential link between specific lncRNA
and the presence of a type I IFN signature remains unclear in SSc. In this study, we
identified, by RNA sequencing, a group of lncRNAs related to the IFN and anti-viral
response consistently modulated in a type I IFN-dependent manner in humanmonocytes
in response to TLR4 activation by LPS. Remarkably, these lncRNAs were concurrently
upregulated in a total of 46 SSc patients in different stages of their disease as
compared to 18 healthy controls enrolled in this study. Among these lncRNAs, Negative
Regulator of the IFN Response (NRIR) was found significantly upregulated in vivo in
SSc monocytes, strongly correlating with the IFN score of SSc patients. Weighted
Gene Co-expression Network Analysis showed that NRIR-specific modules, identified
in the two datasets, were enriched in “type I IFN” and “viral response” biological
processes. Protein coding genes common to the two distinct NRIR modules were
selected as putative NRIR target genes. Fifteen in silico-predicted NRIR target genes
were experimentally validated in NRIR-silenced monocytes. Remarkably, induction of
CXCL10 and CXCL11, two IFN-related chemokines associated with SSc pathogenesis,
was reduced in NRIR-knockdown monocytes, while their plasmatic level was increased
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in SSc patients. Collectively, our data show that NRIR affects the expression of ISGs and
that dysregulation of NRIR in SSc monocytes may account, at least in part, for the type
I IFN signature present in SSc patients.
Keywords: long non-coding RNAs, monocytes, systemic sclerosis, interferon, NRIR
INTRODUCTION
Toll-like receptor 4 (TLR4) is a member of the pattern
recognition receptors (PRR) family, which detects conserved
structures found in a broad range of pathogens and triggers
innate immune responses. TLR4 signals through two major
pathways: (i) the MyD88-dependent pathway, that elicits the
release of pro-inflammatory cytokines, such as TNF-α, IL-6, and
IL-12p40; (ii) the TRIF (Toll/IL-1R domain-containing adaptor-
inducing IFN-beta)-dependent pathway, that contributes to pro-
inflammatory cytokine responses and, most importantly, induces
type I IFN responses, particularly IFN-β (1). IFNs confer
their activity by regulating networks of interferon-stimulated
genes (ISGs), a process that requires de novo transcription
and translation of both IFN and downstream ISGs (2). Other
than being activated by different exogenous pathogen-associated
molecular patterns (PAMPs), the IFN pathway is activated also
by TLR4 ligation of endogenous danger-associated molecular
patters (DAMPs) released upon cell damage or stress (3, 4).
Thus, TLR4-mediated activation of innate immunity plays a
key role not only in host defense against pathogens but also
in numerous autoimmune diseases, including systemic sclerosis
(SSc) (5). Indeed, endogenous ligand-induced TLR4 activation
has been recognized as a key player driving the persistent fibrotic
response in SSc (5–7). Different endogenous TLR4 ligands,
including fibronectin extra domain A (FnEDA) and S100A8/A9,
are indeed increased in the circulation of SSc patients and have
been correlated with fibrotic-related clinical complications (8, 9).
Moreover, activation of TLR4 response leads to transforming
growth factor-β production, a crucial mediator for fibrosis
development in SSc (10).
Likewise, production of type I interferon is closely linked to
TLR4-mediated innate immune signaling in SSc (11–13). In fact,
several lines of evidence suggest that both the IFN network and
monocytes are implicated in SSc immune-pathogenesis. First, the
development of SSc has been reported in patients undergoing
IFN treatment (14) and IFN-α injections worsen SSc-related
clinical features (15). Most importantly, increased expression of
type I IFN-regulated genes, known as “type I IFN signature,” is a
hallmark of SSc, and type I IFN signature is present both in the
fibrotic skin and in peripheral blood cells (11, 13), as well as in
monocytes of SSc patients from the earliest phases of the disease,
even before the skin fibrosis is evident (16). Moreover, in the
fibrotic subsets of SSc patients we identified an increase in non-
classicalmonocytes spontaneously producing the IFN-responsive
CXCL10 (17), a chemokine associated with faster progression
rate from pre-fibrotic SSc to worse disease stages (18).
The IFN pathway downstream TLR4 activation has been
focus of intense investigation and a number of known protein-
mediated mechanisms that mediate the complex signaling
pathways and gene expression programs involved in the
interferon response have been identified (2). Recent studies
point at long non-coding RNAs (lncRNAs) as a novel class
of IFN pathway regulatory molecules (19). LncRNAs are RNA
transcripts longer than 200 nucleotides, characterized by lacking
protein coding capability, but able to regulate gene expression
both at the transcriptional and post-transcriptional levels (20).
Existing data indicate that lncRNAs are critically involved in
various biological and immunological processes (21), including
several pathways related to innate immunity (22–29). However,
with respect to the IFN response, while IFN-induced changes
in the expression of protein-coding RNAs and their functional
outcome have been well-documented, our knowledge of the
impact of IFNs on lncRNA genes is highly incomplete. Moreover,
the involvement of lncRNAs in diseases such as SSc, where both
TLR4 and type I IFN concur to disease pathogenesis, is still
unexplored.
This study aims to investigate the profile and the role of
lncRNAs in the IFN response initiated by TLR4 activation of
primary human monocytes and their implication in the immune
dysregulation present in SSc patients.
MATERIALS AND METHODS
Patients
Patients affected by systemic sclerosis (SSc) and sex- and
age-matched healthy controls (HC) were obtained from the
University Medical Center Utrecht (UMCU), The Netherlands,
and the Scleroderma Unit of Fondazione IRCCS Policlinico of
Milan, Italy. Patients fulfilling the ACR/EULAR 2013 criteria
(30) were classified in relation to the extent of skin fibrosis as
limited cutaneous (lcSSc) or diffuse cutaneous SSc (dcSSc) (31);
patients satisfying the classification criteria without skin fibrosis
were referred to as non-cutaneous SSc (ncSSc). Additionally,
early SSc (eaSSc) subjects were defined as patients presenting
with Raynaud’s phenomenon and SSc-specific autoantibodies
and/or typical nailfold videocapillaroscopy abnormalities (32).
Three separate cohorts, herein named “definite SSc” cohort,
“non-fibrotic SSc” cohort, “SSc cohort 3,” were recruited for
the current study. Demographics and clinical characteristics of
the three cohorts are reported in Tables 1–3. All patients and
healthy donors signed an informed consent form approved by
the local institutional review boards prior to participation in the
study. Samples and clinical information were made de-identified
immediately after collection.
Cell Purification and Culture
Human CD14+ monocytes and neutrophils (PMNs) were
purified from heparinised whole blood of SSc patients and
matched HC or from buffy coats of healthy donors after
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TABLE 1 | Demographics and clinical characteristics of the donors included in the
definite SSc cohort.
Patient group (n) HC (9) ncSSC (7) lcSSc (11) dcSSc (7)
Age (yr.) 52 (30–64) 45 (26–63) 59 (45–70) 58 (34–72)
Female (n, %) 5 (56%) 6 (86%) 8 (73%) 3 (43%)
ANA (n pos, %) – 6 (86%) 10 (91%) 7 (100%)
ACA (n pos, %) – 3 (43%) 6* (55%) 1 (14%)
Scl70 (n pos, %) – 2 (29%) 2* (18%) 4 (57%)
mRSS – 0 6 (0–12) 14* (5–36)
ILD – 1 (14%) 2 (18%) 5 (71%)
Disease Duration (yr.) 4 (1–12) 9 (1–19) 10 (2–27)
Values reported indicate the number (n) of patients and the median for each parameter
[Interquartile Range (IQR)], if not otherwise indicated. ACA, anticentromere antibodies;
ANA, antinuclear antibodies; dcSSc, diffuse cutaneous SSc; HC, healthy controls; ILD,
Interstitial Lung disease; lcSSc, limited cutaneous SSc; mRSS, modified Rodman Skin
score; ncSSc, non-cutaneous SSc; pos, positivity; Scl70, anti-topoisomerase antibodies;
Yr., years.
*1 patient unknown.
TABLE 2 | Demographics and clinical characteristics of the donors included in the
non-fibrotic SSc cohort.
Patient group (n) HC (9) eaSSC (11) ncSSc (10)
Age (yr.) 38 (28–49) 57 (40–77) 52 (25–70)
Female (n, %) 9 (100%) 11 (100%) 10 (100%)
ANA (n pos, %) – 10 (91%) 10 (100%)
ACA (n pos, %) – 7 (64%) 8 (80%)
Scl70 (n pos, %) – 2 (18%) 1 (10%)
mRSS – 0 0
ILD – 0 0
Disease Duration (yr.) – – Unknown
Values reported indicate the number (n) of patients and the median for each parameter
[Interquartile Range (IQR)], if not otherwise indicated. ACA, anticentromere antibodies;
ANA, antinuclear antibodies; eaSSc, early SSc; HC, healthy controls; ILD, Interstitial Lung
disease; mRSS, modified Rodman Skin score; ncSSc, non-cutaneous SSc; pos, positivity;
Scl70, anti-topoisomerase antibodies; Yr., years.
centrifugation over Ficoll-Paque gradient. Briefly, CD14+
monocytes were purified from PBMCs using the anti-CD14
microbeads (Miltenyi Biotec), on the autoMACs Pro Separator
(Miltenyi Biotec) according to manufacturer’s protocol. Purity
of monocyte preparations was usually >98%. PMNs were
recovered after dextran sedimentation and hypotonic lysis of
erythrocytes followed by EasySep neutrophil enrichment kit
(StemCell Technologies, Vancouver, Canada) (33). Purity of
neutrophils preparations was usually 99.7± 0.2%.
Monocytes (3 × 106 cells/ml) and PMNs (5 × 106 cells/ml)
were cultured in RPMI 1640 (Gibco) supplemented with
10% FCS (<0.5 EU/ml; Sigma-Aldrich) and 2mM Glu in the
presence or absence of 100 ng/ml ultra-pure lipopolysaccharide
(LPS, from E. coli strain O111:B4, InvivoGen, San Diego, CA,
USA), 5µM R848 (Invivogen), 1,000 U/ml IFNα CRI003B,
Cell Sciences), 100 ng/ml palmitoyl-3-cysteine-serine-lysine-4
(Pam3CSK4, Invivogen), 50µg/ml polynosinic:polycytidylic
acids [poly(I:C), Invivogen], as indicated. In selected
experiments, CD14+ monocytes were incubated for 30min
with 5µg/ml Brefeldin A (BFA, Sigma-Aldrich) or 5µg/ml
αIFNAR (PBL InterferonSource, Piscataway, NJ, USA) or its
isotype control antibody (mouse IgG2a), before cell stimulation.
Human Monocyte Transfection
Freshly purified monocytes (8 × 106) were transfected with
200 pmol NRIR-specific Silencer Select siRNA or Silencer
Select negative control #2 (both from Ambion, Thermo
Scientific), using the Human Monocyte Nucleofector Kit and
the AMAXA Nucleofector II device (both from Lonza),
according to the manufacturer’s protocol. Once transfected,
cells were plated in recovery medium [50% RPMI 1640 +
10% FCS + 2mM Glu, and 50% IMDM (Lonza) + 10%
FCS + 2mM Glu], at 3 × 106 cells/ml overnight. The
next day, medium was changed to RPMI 1640 + 10% FCS
+ 2mM Glu, and cells were stimulated as indicated. NRIR
specific Silencer Select siRNA sequence (34) is reported in
Table S1.
Extraction of Total RNA
Total RNA was purified with the RNeasy Mini Kit (Qiagen),
according to the manufacturer’s instructions. DNAse treatment
(RNAse Free DNase I set, Qiagen) on column was performed.
RNA quantification, purity and integrity were assessed at
the Nanodrop 2000 spectrophotometer (Thermo Scientific)
and by capillary electrophoresis on an Agilent Bioanalyzer
(Agilent Technologies), respectively. Purified RNA was used for
sequencing analysis or RT-qPCR, as described below.
RNA Sequencing Analysis
RNA sequencing data of peripheral blood monocytes purified
from SSc, together with sex- and age-matched healthy controls
(HC) enrolled in the “definite SSc” cohort, were obtained
from the University Medical Center Utrecht (UMCU), The
Netherlands (35).
RNA sequencing libraries were generated from total RNA
extracted from CD14+ monocytes of SSc patients and matched
HC enrolled in the “definite SSc” and “non-fibrotic SSc”
cohorts, or from RNA pools of three different donors of
freshly isolated and LPS-treated monocytes. RNA-seq library
preparation was accomplished using the TruSeq RNA Sample
Prep Kit v2 (Illumina Inc., San Diego, CA, USA). Libraries
were sequenced on a HiSeq 2000 system (Illumina) using
pair-end sequencing reads (2 × 90 bp for SSc and matched
HC libraries and 2 × 51 bp for resting and LPS-treated
monocytes libraries); a minimum of 20 million fragments per
sample were analyzed. After quality filtering according to the
Illumina pipeline, reads were firstly aligned to the human
transcriptome annotated in Ensembl 77 (Homo sapiens gene
model annotation) and secondly converted to genomic mapping
using as reference the human reference genome GrCh38
(Genome Reference Consortium Human build 38) by means of
TopHat (v 2.0.14) (36). On average, 23,969,150 (concordant pair
alignment rate: 91.84%), 24,404,133 (concordant pair alignment
rate: 89.90%), and 43,071,006 (concordant pair alignment rate:
92.67%) paired-reads of the “definite SSc,” “non-fibrotic SSc”
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and LPS-treated-monocytes dataset, respectively, mapped to the
reference genome.
Differential expression analysis was performed using the
generalized linear model (GLM) implemented in DESeq2 (v
1.6.3) on the summed exon reads count per gene estimated
using HTSeq-count (v 0.6.1p1) (37, 38). Differentially expressed
genes were identified from the comparison of each single SSc
group and matched HC. Significance was tested using the Wald
test. Genes with a log2(FC) value ≥0.58 or ≤-0.58 and a
p ≤ 0.05, were considered significantly modulated. Differentially
expressed genes in LPS-treated monocytes were identified using
the Likelihood Ratio Test (LRT). Raw p-values from differential
expression analyses were adjusted to control the false discovery
rate (FDR) using the Benjamini–Hochberg method. Genes with
adjusted p < 0.05 were considered significantly modulated
by LPS. Gene expression levels were expressed as variance
stabilized data (vsd) or FPKM, calculated according to DESeq2
instructions. Gene type were associated according to the Ensembl
77 annotation. All genes not belonging to the gene type protein
coding and pseudogene andwith a transcript length of at least 200
bp were considered as lncRNAs. Raw and processed sequencing
data are available from Gene Expression Omnibus under the
following accession numbers: GSE123532 and GSE124075.
Gene Expression Data of PBMC From SLE
Patients and Relative Healthy Controls
Gene expression profiles of PBMC purified from systemic lupus
erythematosus (SLE) and relative healthy donors (HC) were
downloaded from Gene Expression Omnibus Database (GEO
number: GSE122459). Gene expression levels and differential
expression analysis were retrieved from the dataset present in the
GEO database.
GO-Term and Pathway Enrichment
Analysis
Protein coding genes (PCGs) were subjected to Gene Ontology
(GO) and pathway enrichment analysis using ToppFun1 (39).
p-value was calculated according to the probability density
function and corrected for the False Discovery Rate (FDR)
according to Benjamini-Hochberg method. Pathways and GO-
terms associated to biological processes (BP) with a FDR≤0.05
were considered significantly enriched.
Weighted Gene Co-expression Network
Analysis
Co-expression networks were generated using WGCNA R-
package (40). Signed weighted adjacency matrix of connection
strengths was constructed using the soft-threshold approach with
a scale-independent topological power β = 18 for LPS-treated
and freshly isolated monocytes and β = 13 for the definite
SSc data. Genes were aggregated into modules by hierarchical
clustering and refined by the dynamic tree cut algorithm.
Biological function of each module was evaluated by pathway
and BP GO-terms enrichment analysis using ToppFun (39). All
terms enriched with a FDR< 0.05, were considered. Redundancy
1https://toppgene.cchmc.org/enrichment.jsp
of significantly enriched BP GO-terms was solved by means of
REVIGO (41) using the simRel score to assess similarity between
two GO-terms (42). NRIR-specific modules were visualized using
Cytoscape v3.2.1 (43).
Gene Expression Analysis by Real-Time
PCR
RNA samples were reverse transcribed using 5 ng/µl random
primers, 1 U/µl RNase inhibitor (RNAse Out, Invitrogen)
and 5 U/µl reverse transcriptase (SuperScript III, Invitrogen),
according to manufacturer’s instruction. NRIR expression
was quantified in duplicates by RT-qPCR from 9 ng RNA-
equivalent cDNA in the presence of SYBR Select Master Mix
(ThermoFisher Scientific, Applied Biosystems) and 400 nM
specific primers (Table S1), on the ViiATM 7 Real-Time PCR
System (ThermoFisher Scientific, Applied Biosystems) using the
standard protocol. PCG expression was quantified in duplicates
by RT-qPCR from 9 ng RNA-equivalent cDNA in the presence of
Fast SYBR Green Master mix (ThermoFisher Scientific, Applied
Biosystems) and 200 nM of specific primer pairs (Table S1), on
the ViiATM 7 Real-Time PCR System (ThermoFisher Scientific,
Applied Biosystems). Primers were designed using the Oligo
Explorer software2, for only fifty-six out seventy-nine NRIR
putative target genes was possible to design specific primer pairs.
Data were analyzed with LinReg PCR 7.03 and Q-Gene software4
Gene expression was calculated as mean normalized expression
[MNE (44)] units after normalization over the stably expressed
RPL32 or ACTIN B.
Multiplex Immunoassay
CXCL10, CXCL11, and CCL8 concentrations in cell-free
supernatants and/or plasma from SSc patients and matched
HC enrolled in the “SSc cohort 3” were measured using an
in-house developed and validated (ISO9001 certified) multiplex
immunoassay (Laboratory of Translational Immunology,
University Medical Center Utrecht) based on Luminex
technology (xMAP, Luminex Austin TX USA). The assay was
performed as previously described (45). Aspecific heterophilic
immunoglobulins were pre-absorbed from all plasma samples
with heteroblock (Omega Biologicals, Bozeman MT, USA). All
samples were measured with the Biorad FlexMAP3D (Biorad
laboratories, Hercules USA) in combination with the xPONENT
software (v 4.2, Luminex). Data were analyzed by a 5-parametric
curve fitting using the Bio-Plex Manager software (v 6.1.1,
Biorad).
Statistical Analysis
Data are expressed as mean ± SEM unless otherwise indicated.
Statistical evaluation was determined using the Mann Whitney
test or the two-way analysis of variance (ANOVA), followed
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TABLE 3 | Demographics and clinical characteristics of the donors included in the SSc cohort 3.
Patient group (n) HC (21) eaSSc (15) ncSSc (27) lcSSc (23) dcSSc (19)
Age (yr.) 52 (35–82) 62 (25–81) 59 (29–80) 60 (41–80) 52 (27–80)
Female (n, %) 19 (90%) 15 (100%) 27 (100%) 22 (96%) 15 (79%)
ANA (n pos, %) – 15 (100%) 26 (96%) 22 (96%) 16 (84%)
ACA (n pos, %) – 12 (80%) 20 (74%) 12 (52%) 0 (0%)
Scl70 (n pos, %) – 2 (13%) 1 (4%) 9 (39%) 11 (58%)
mRSS – 0 0 4 (0–8) 12 (2–29)
ILD – 0 2 (7%) 7 (30%) 14 (74%)
Disease Duration (yr.) – N.A. 10* (0–29) 16** (1–38) 10 (1–25)
Values reported indicate the number (n) of patients and the median for each parameter [Interquartile Range (IQR)], if not otherwise indicated. ACA, anticentromere antibodies; ANA,
antinuclear antibodies; dcSSc, diffuse cutaneous SSc; eaSSc, early SSc; HC, healthy controls; ILD, Interstitial Lung disease; lcSSc, limited cutaneous SSc; mRSS, modified Rodman
Skin score; N.A., not assessed; ncSSc, non-cutaneous SSc; pos, positivity; Scl70, anti-topoisomerase antibodies; Yr., years.
*2 patients unknown.
**3 patients unknown.
were performed using the rcorr() function in R using the non-
parametric Spearman method. Correlation with p < 0.05 were
considered significant.
RESULTS
Identification of LPS-Modulated lncRNAs
in Primary Human Monocytes
To identify lncRNAs potentially involved in the responses of
peripheral human monocytes downstream TLR4 activation,
CD14+ monocytes purified from buffy coats of healthy donors
were cultured in the presence or absence of LPS (100 ng/ml)
for 1.5 h or 4 h, and subsequently subjected to RNA sequencing.
1,812 transcripts annotated as lncRNAs in Ensemble (Figure 1A)
were identified as significantly (p-adj < 0.05) modulated in
response to LPS. Specifically, 1278 lncRNAs (i.e., 70.53%) were
up-regulated, while 534 lncRNAs (i.e., 29.47%) were down-
regulated (Figure 1B). Moreover, K-means clustering arranged
the LPS-modulated lncRNAs in three main groups according
to their kinetic of expression (Figure 1C): (i) lncRNAs rapidly
and consistently modulated by LPS within 1.5 h, representing
the majority (52.32%) of LPS-modulated lncRNAs (early group,
Figure 1D); (ii) lncRNAs modulated by LPS within 1.5 h
in a transient manner (22.57%) (early and transient group,
Figure 1E); (iii) lncRNAs modulated by LPS at 4 h (25.11%) (late
group, Figure 1F).
Identification of Type I IFN
Signature-Associated lncRNAs
LncRNAs possibly involved in the regulation of type I IFN
pathway activated downstream TLR4 were identified using the
strategy depicted in Figure 2. Specifically, 3,248 PCGs up-
regulated in response to LPS (FPKM > 2) were retrieved and
subjected to GO term enrichment analysis. 469 LPS-induced
PCGs associated to significantly enriched IFN-response and
anti-viral response-related GO-terms were then subjected to
correlation analysis with the 1,812 LPS-modulated lncRNAs.
Finally, based on the knowledge that lncRNAs can regulate the
transcription of PCGs located in cis (46), only the lncRNAs
localized in cis (± 150Kb) to correlated PCGs were retrieved
(n = 99) (Figure 2 and Table S2). This group of lncRNAs
(n = 99) will be referred from now on as the “IFN/viral”
lncRNAs.
To verify whether the selected “IFN/viral” lncRNAs were
effectively related to the IFN signature in an in vivo setting
where the IFN pathway is known to play a pathogenetic role, the
expression level of the 99 selected lncRNAs was then retrieved
and analyzed from the transcriptomic profile of monocytes
purified from the “definite SSc” (35) and “non-fibrotic SSc”
cohorts of patients andmatched healthy donors (Tables 1, 2). The
patient cohorts included individuals presenting with different SSc
phenotypes according to clinical features and the extent of skin
fibrosis, i.e., early SSc (eaSSc, n= 11), non-cutaneous SSc (ncSSc,
n= 17), limited cutaneous SSc (lcSSc, n= 11), diffuse cutaneous
SSc (dcSSc, n= 7).
Four out of ninety-nine lncRNAs, namely NRIR, PSMB8-
AS1, RP5-1091N2.9, and RP11-24F11.2, were expressed at
significantly higher levels in at least two groups of SSc patients
as compared to their respective healthy donors in the “definite
SSc” cohort (Figure 3A), whereas only NRIR was significantly
up-regulated in ncSSc and showed a trend in eaSSc (FC = 1.30,
p= 0.104) in the “non-fibrotic” cohort (Figure 3B). Remarkably,
only the expression of NRIR significantly correlated in both
cohorts with the patients’ IFN score (Figures 3C,D), calculated
on the basis of the expression of IFI27, IFI44L, IFIT1, IFIT2,
IFIT3, and SERPING1 (16).
IFNα was demonstrated to be central to the pathogenesis
also of other systemic autoimmune diseases, with Systemic
lupus erythematosus (SLE) being the prototype one. To verify
whether NRIR is effectively related to the IFN signature in
an in vivo setting in IFN-related diseases other than SSc,
we retrieved from the Gene Expression Omnibus database
RNA-seq data from PBMCs of SLE patients and matched
healthy controls (GSE122459). Seventeen out of ninety-nine
lncRNAs were commonly modulated in LPS-treated CD14+
transcriptome and SLE PBMCs compared to healthy controls
(Figure S1A), and only three lncRNAs, namely NRIR, PSMB8-
AS1 and RP5-1091N2.9, were modulated in all the three datasets
Frontiers in Immunology | www.frontiersin.org 5 January 2019 | Volume 10 | Article 100
Mariotti et al. NRIR-IFN Signature Regulatory Axis
FIGURE 1 | LPS modulates the expression of long noncoding transcripts in human monocytes. CD14+ monocytes were cultured for 1.5 or 4 h with LPS (100 ng/ml)
or left untreated (t0). Two pools of three donors for each condition were used to create polyA library for RNA-seq. Sequencing data were analyzed as described in
Materials and Methods. The expression levels of the LPS-modulated (adjusted p < 0.05) lncRNAs (A) are shown as row mean-centered z-Score of the variance
(Continued)
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FIGURE 1 | stabilized data (vsd). (B) The percentage of up- and down-regulated lncRNAs modulated by LPS. (C) The percentage of early, early & transient and late
lncRNAs modulated by LPS. K-means clustering analysis was applied on the significantly modulated lncRNAs. Early modulated (D), early and transiently modulated
(E) as well as late modulated (F) lncRNAs are shown. The expression of each lncRNA belonging to the three groups is shown. LncRNAs up regulated and down
regulated by LPS are shown separately. NRIR expression is highlighted in red. LncRNA expression is depicted as row mean-centered z-Score of the variance
stabilized data (vsd), number of lncRNA belonging to each KMC group is shown.
FIGURE 2 | Analysis pipeline to identify IFN/viral-related lncRNAs, modulated by LPS in monocytes. Green squares represent the selection of IFN/viral related protein
coding genes, while the purple square represents the selected lncRNAs modulated by LPS. Black squares represent the workflow for integration of protein coding
genes and lncRNAs by correlation analysis.
(i.e., LPS-treated CD14+ monocytes, SSc CD14+ monocytes
and PBMC from SLE patients) (Figure S1B). Remarkably, NRIR
was the only one lncRNA significantly up-regulated in all the
three datasets and the lncRNA most differentially expressed
(log2FC = 1.90, p = 3.83 × 10−8) in PBMC from SLE patients
as compared to healthy controls (Figure S1B).
Collectively, data from three different biological datasets
(i.e., transcriptome of monocyte activated in vitro by LPS,
transcriptome of circulating monocytes from SSc patients and
transcriptome of PBMC from SLE patients) converged in
identifying NRIR as belonging to the IFN signature. Therefore,
we focused our study on the pathways underlying NRIR
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FIGURE 3 | NRIR expression is increased in monocytes from SSc patients and correlates with the IFN-score. RNA sequencing data of CD14+ monocytes from SSc
patients and matched healthy controls (HC) from both the definite SSc and non-fibrotic SSc cohorts were analyzed as described in Meterials and Methods. NRIR,
PSMB8-AS1, RP5-1091N2.9, and RP11-24F11.2 expression were considered. LncRNAs expression in HC and patients with established Systemic Sclerosis (ncSSc,
lcSSc, and dcSSc, definite-SSc cohort) (A) and in patients with early stages of SSc (eaSSc and ncSSc, non-fibrotic SSc cohort) (B) is shown. *p < 0.05, **p < 0.01,
***p < 0.001, ns, not significant, by Wald test (C) Correlation of NRIR expression with the IFN-score of HC (gray), ncSSc (red), lcSSc (green), and dcSSc (blue)
patients is depicted. (D) Correlation of NRIR expression with the IFN-score of HC (gray), eaSSc (black) and ncSSc (red) patients is shown. Spearman’s Rho and
p-value are reported. NRIR expression levels are expressed as vsd, IFN Score was calculated according to Brkic et al. (16).
upregulation as well as on the role of this lncRNA in the type I
IFN signature.
NRIR Is a Type I IFN Dependent lncRNA
Consistent with KMC analysis of RNA-seq data that classified
NRIR as a “late” transcript (Figure 1F, red line), kinetic
analysis confirmed that NRIR expression is slowly induced by
LPS stimulation in monocytes, being detectable after 4 h and
steadily increasing over 16 h (Figure 4A). In addition, monocyte
activation with agonists of TLR3 [polyinosinic:polycytidylic acid,
poly(I:C)] and TLR7/8 (Resiquimod, R848), both known to
promote type I IFN production, resulted in up-regulation of
NRIR (Figure 4B). Conversely, a synthetic lipoprotein agonist of
TLR2 (Pam3CSK4), unable to induce type I IFN transcription
and secretion (47), was ineffective (Figure 4B). Consistent with
this observation, treatment of monocytes with brefeldin A
or with IFNα receptor (αIFNAR) blocking antibodies before
LPS stimulation completely abolished NRIR induction by LPS
(Figure 4C), indicating that endogenously produced type I IFNs
is responsible for the upregulation of NRIR. Additionally, NRIR
expression is significantly induced by IFNα but not by LPS,
in human polymorphonuclear neutrophils (PMNs), that do
not activate the IFN pathway downstream TLR4 (Figure 4D)
(48). Taken together, these data demonstrate that type I
IFN production is necessary and sufficient to increase NRIR
expression in response to LPS.
The Type I IFN-Dependent NRIR Plays a
Role in the Expression of Several ISGs
Identification of pathways likely associated to NRIR function was
conducted by weighted gene co-expression analysis (WGCNA).
Two specific co-expression networks were created, one composed
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FIGURE 4 | Induction of NRIR expression is IFN-dependent. (A) CD14+ monocytes were cultured for the indicated time point in presence of LPS (100 ng/ml, black
line) or left untreated (gray line). NRIR expression levels were analyzed by RT-qPCR and expressed as mean normalized expression (MNE). Results are shown as mean
± SEM of three experiments. **p < 0.01, ***p < 0.001 by two-way ANOVA. (B) CD14+ monocytes were stimulated with Pam3CSK4 (100 ng/ml), poly(I:C) (50µg/ml),
R848 (5µM) or left untreated for the indicated time points. NRIR expression levels were analyzed by RT-qPCR and expressed as MNE. One experiment representative
of two performed is shown. (C) CD14+ monocytes were stimulated with LPS or left untreated for 8 h in presence or absence of brefeldin A (BFA, left) or αIFNAR or the
control IgG2a antibody (right). NRIR expression levels were analyzed by RT-qPCR and expressed as MNE. For BFA experiments results are shown as mean ± SEM of
three experiments, *p < 0.05 by two-way ANOVA, while for αIFNAR experiments one experiment representative of two performed is shown. (D) Human neutrophils
were stimulated with LPS (100 ng/ml), IFNα (1,000 U/ml) or left untreated for 5 and 18 h. NRIR expression levels were analyzed by RT-qPCR and expressed as MNE.
Results are shown as mean ± SEM of three experiments. *p < 0.05, ***p < 0.001 by two-way ANOVA.
of 13 modules in the transcriptome of LPS-treated monocytes
and the second one composed of 26 modules in the “definite
SSc” cohort. The NRIR-related module was identified in both
LPS-treated monocytes (blue module) and SSc monocytes (cyan
module) co-expression networks. The blue module contained
2060 PCGs and 548 ncRNAs (Figure S2), while the cyan module
was composed of 116 PCGs and 8 ncRNAs (Figure S3).
GO-term and pathway enrichment analysis of the PCGs of
each module underlined that biological processes related to
“response to type I IFN,” “response to virus,” and “immune
system process” (Figure 5) and related pathways (Tables S3,
S4) were significantly enriched in both modules. Comparative
analysis of the two modules identified 83 common transcripts:
specifically, 79 PCGs and 4 ncRNAs (Figure 6A), the majority
(63.3%) of which were associated to IFN, antiviral and immune
response (Figure 6B). The 79 common PCGs were selected as
putative NRIR target genes.
To investigate the role of NRIR in the regulation of
IFN and anti-viral response secondary to TLR4 activation,
we analyzed the expression of 56 PCGs, that were co-
expressed with NRIR and common to the both blue and cyan
modules (Figure 6), in NRIR-silenced monocytes. Monocyte
transfection with NRIR siRNA led to an average reduction
of 60.83 ± 4.81 and 55.47 ± 4.83% of the constitutive and
LPS induced NRIR expression, respectively (Figure 7A). Under
these conditions, the induction of fifteen PCGs by LPS was
significantly impaired as compared to cells transfected with a
scramble siRNA (Figures 7B–P). Precisely, decreased induction
of CXCL10, CXCL11, APOBEC3A, MX1, USP18 mRNA was
observed 4 h after LPS stimulation and remained reduced at
8 h as well; decreased induction of CCL8, EPSTI1, DDX58,
IFI44, IFIH1, IFIT2, and OAS2 was observed at shorter time
point (4 h); whereas the ability of LPS to upregulate the
expression of IFITM3, ISG15 and OAS3 could be detected only
at later time point (8 h) (Figures 7B–P). The induction of the
remaining forty-one PCGs was unaffected by NRIR knock-
down (Figures S4, S5), Strikingly, all genes modulated by NRIR
silencing were also significantly upregulated in at least one group
of SSc monocytes as compared to cells isolated from healthy
donors (Figure S3).
Among the IFN-responsive genes, CXCL10, CXCL11 and
CCL8 have been shown to be implicated in SSc pathogenesis
and/or to correlate with the degree of skin fibrosis (18, 49–51).
Analysis of CXCL10, CXCL11 and CCL8 protein level in cell-free
supernatants of LPS-stimulated monocytes showed a significant
reduction of CXCL10 (mean reduction: 62.48 ± 8.94%, n = 7)
and CCL8 (mean reduction: 56.13 ± 7.37%, n = 7) production
in response to LPS (Figures 8A,B), while CXCL11 was below the
detection levels (not shown). Noticeably, plasma level of CXCL10
and CXCL11 in the SSc subjects enrolled in this study was
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significantly higher as compared to their healthy counterparts
(Figures 8C,D).
Collectively, these data substantiate the role of NRIR in the
expression of several interferon-responsive genes upregulated by
LPS in vitro or constitutively increased in circulating monocytes
from SSc patients.
DISCUSSION
The aim of this study was to investigate the potential role of
lncRNAs in the type I IFN pathway elicited in human monocytes
by TLR4 activation and to explore their functional role in vivo,
in the IFN signature displayed by SSc monocytes. Several studies
have shown that lncRNAs are involved in numerous aspects of the
innate and adaptive immune responses (22), and, more recently,
a critical role for a small group of lncRNAs in the regulation
of the IFN response has been reported (19). Likewise, evidence
clearly supports the involvement of lncRNAs in the pathogenesis
of autoimmune and inflammatory diseases (25, 31), where the
physiologic response of immune cells is dysregulated. However,
no lncRNA has been associated to the immune dysregulation
present in SSc yet. Characterization of the role of lncRNAs in
the regulation of monocytes IFN response to TLR4 activating
agents is an important aspect to understand both the physiologic
response and the disease biology of SSc arising from alteration
of physiologic pathways. In fact, the link between monocytes,
TLR4 activation and the downstream IFN response with SSc
pathogenesis is supported by several observations: (i) circulating
monocytes have been indicated as one prominent leukocyte
subset playing a role in the pathogenesis of SSc (52–55); (ii)
circulating SSc monocytes are characterized by an increased type
I IFN signature (11, 12, 16) (iii) TLR activation may represent the
connection between immune activation in SSc and tissue fibrosis
(7, 10, 52, 56).
The lncRNA landscape of LPS-activated human monocytes,
characterized by RNA sequencing, identified 1,278 annotated
lncRNAs as upregulated and 534 as downregulated. Modulated
lncRNAs were further clustered according to their kinetic of
expression into early, early and transient and late. Correlation
with the expression of PCGs enriched in the IFN- and anti-
viral response related GO-terms allowed us to retrieve lncRNAs
likely comprised into the type I IFN pathway. Moreover, as
some lncRNAs have been described to regulate the expression
of neighboring genes (46), lncRNAs that may have functional
relevance in the expression of LPS-induced mRNAs related to
the IFN/anti- viral response were retrieved on the basis of their
localization in cis to their respective correlated PCGs.
To validate the relevance of these “IFN/viral” lncRNAs in
an in vivo setting where the IFN response constitute a major
hallmark, we examined the expression level of each of the 99
lncRNAs in monocytes from two distinct cohorts of SSc patients
as compared to the relative healthy control groups. The cohorts
comprised patients with the full spectrum of SSc phenotypes,
from pre-clinical eaSSc, to definite groups either presenting
with (lcSSc and dcSSc) or without (ncSSc) skin fibrosis. Most
importantly in both cohorts a remarkable IFN signature had been
FIGURE 5 | NRIR is implicated in biological processes related to immune
response and the IFN/antiviral response. GO-term enrichment analysis was
performed to identify biological processes enriched in the blue- (A) or the
cyan-module (B). Significantly enriched GO terms are represented as circles
according to their semantic similarities. Circle size represents term specificity
(bigger, general terms; smaller, specific terms), while circle color represents the
log10 (p-value FDR B&H) of the enrichment.
identified in previous studies (16, 35). Remarkably, monocytes
from lcSSc and ncSSc patients showed consistently higher levels
of NRIR expression, that correlated significantly with the IFN
signature in both cohorts analyzed, strikingly confirming the
implication of NRIR in the IFN response also in a pathological
condition. Consistently, it must be noted that NRIR had the
highest expression levels in patients with ncSSc, that is the
SSc subset presenting with the strongest IFN-signature (16). In
addition, it is intriguing to observe that NRIR shows a trend of
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FIGURE 6 | PCGs common to the blue and cyan modules are mainly involved in the immune and IFN/antiviral response. (A) Representation of the transcripts
common to blue and cyan-module. The seventy-nine protein coding genes and the four ncRNAs are represented as rectangles and triangles, respectively. Transcripts
are grouped according to their associated biological process related GO-terms. Different colors highlight different group of GO-terms, the most general GO term,
summarizing each group, is reported. Genes associated to any GO-term are signed as not associated and depicted in gray. (B) Protein coding genes found in both
modules are associated to their GO terms. Percent of common protein coding genes associated to different GO terms is shown.
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FIGURE 7 | NRIR regulates fifteen of its co-expressed genes. CD14+ monocytes were transfected with si-NRIR or si-CTR and 18 h later were stimulated with LPS for
4 or 8 h or left untreated. The expression of NRIR (A) and its co-expressed genes (B–P) was analyzed by RT-qPCR and expressed as MNE. Results are shown as
mean ± SEM of at least three different experiments. *p < 0.05, **p < 0.01, ***p < 0.001 by two-way ANOVA.
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FIGURE 8 | NRIR regulated proteins CXCL10 and CXCL11 are elevated in plasma of SSc patients. CD14+ monocytes from seven different donors were transfected
with si-NRIR or si-CTR and 18 h later were stimulated with LPS for 8 h. Cell-free supernatants were collected, and the release of CXCL10 (A) and CCL8 (B) was
measured by the multiplex immunoassay. *p < 0.05 by Wilcoxon matched-pairs signed rank test. CXCL10 (C) and CXCL11 (D) level in plasma from SSc patients and
matched HC was measured by the multiplex immunoassay. eaSSc, early SSc; ncSSc, non-cutaneous SSc; lcSSc, limited-cutaneous SSc; dcSSc, diffuse-cutaneous
SSc. *p < 0.05, **p < 0.01, ***p < 0.001 by Mann Whitney test.
upregulation also in the eaSSc group, characterized by higher
levels of ISGs as well. Considering that most patients with eaSSc
are prompt to progress toward definite SSc (57, 58), one could
speculate a potential implication of NRIR in the IFN signature
intertwined with SSc progression. Remarkably, NRIR was the
lncRNAmost differentially expressed in PBMC from SLE patients
as compared to healthy controls, thus further supporting that
dysregulation of the IFN-dependent NRIR lncRNA represents a
hallmark of different IFN-driven pathologies.
Identification of NRIR-related pathways was conducted
according to the “guilt-by-association”method (59), that remains
the only approach allowing to characterize lncRNAs based on
the function of their co-expressed PCGs. NRIR was found in
two distinct co-expression modules, retrieved from WGCNA
analysis of the transcriptome of monocyte activated in vitro by
LPS or isolated from SSc patients. The majority (63%) of the
PCGs common to both modules was included in “response to
type I IFN,” “response to virus,” and “immune system process”
biological processes, thus strengthening the likelihood that NRIR
plays a role in these processes. Experimental validation of the in
silico analysis demonstrated that NRIR is a type I IFN-responsive
gene, induced in monocytes upon activation of only those TLRs
that can trigger type I IFN production (i.e., TLR4, TLR3 and
TLR7/8). This is further supported by the demonstration that
inhibition of LPS-induced release of soluble mediators, and
specifically blockade of type I IFN receptor abolished the ability
of LPS to upregulate NRIR. Moreover, monocyte activation with
agonists of TLR2 (unable to induce type I IFN transcription
and secretion) or neutrophil activation of TLR4 (that does not
mobilize the TRIF-IFN pathway) (48) failed to upregulate NRIR
expression.
Consistently with the NRIR role suggested by the WGCNA
approach, data shows that NRIR-silencing mainly reduces the
LPS-induced expression of type I IFN target genes, including,
among the others, CXCL10,MX1, IFITM3, and ISG15.Moreover,
measurements of CXCL10 and CCL8 secretion further endorsed
the role of NRIR as a positive regulator of a subset of LPS-induced
IFN-dependent genes.
The inhibition of ISGs upon NRIR-silencing is in sharp
contrast with recent reports showing that NRIR acts as a negative
regulator of specific ISGs (CMPK2, CXCL10, IFIT3, IFITM1,
ISG15, Viperin, and IFITM3) in hepatocytes (34) or epithelial
cells (60). Overall, our findings strengthen the role of NRIR as
a regulator of the IFN response, but they strongly point out
that NRIR function is highly cell-type or stimulus specific. Such
behavior is not uncommon among lncRNAs implicated in the
regulation of immune response; one example is IL7-AS, that
was described either as a positive regulator of IL-6 expression in
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IL-1β-activate epithelial cells (61) or as negative regulator in LPS-
stimulated monocytes/macrophages as well as in IL-1β activated
chondrocytes (62).
It must be underlined that all the ISGs inhibited by NRIR
silencing are also upregulated in SSc monocytes, that display
concomitantly a prominent IFN signature as well as NRIR
upregulation. These observations strengthen the relevance of the
NRIR-ISGs axis in both physiological as well as pathological
conditions. Among the ISGs inhibited upon NRIR silencing,
numerous genes have been frequently linked to SSc. Increased
levels of CXCL10, CXCL11, IFI44, and MX1 correlate with the
severity of different clinical features in SSc patients (63, 64).
Higher MX1 expression was associated with ischemic ulcers
and reduced forced vital capacity (64, 65). The extent of skin
fibrosis measured by the modified Rodman Skin Score (mRSS)
correlates with the expression of IFI44 (63). Most importantly,
increased levels of circulating CXCL10 and CXCL11, both
NRIR targets, highly correlate with the type I IFN signature
as well as with a more severe clinical phenotype, with lung
and kidney involvement (11, 63, 66). In fact, serum level of
CXCL10 and CXCL11 has been recently proposed as biomarker
for the identification of early and non-fibrotic subset of SSc
(18). Conversely, inhibition of type I IFN signature in SSc
patients with anifrolumab, that blocks IFN receptor signaling,
leads to lower levels of CXCL10 expression and fibrosis-related
transcripts (67).
Collectively, herein we demonstrate that the IFN-dependent
lncRNA NRIR is a positive regulator of the LPS-induced IFN
response in human monocytes and highlight, for the first
time, that aberrant expression of NRIR can be involved in
the dysregulation of immune system intertwined with SSc
development.
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